S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
NASDAQ:CVET

Covetrus - CVET Stock Forecast, Price & News

$20.83
+0.02 (+0.10%)
(As of 08/15/2022 05:07 PM ET)
Add
Compare
Today's Range
$20.80
$20.85
50-Day Range
$20.50
$20.85
52-Week Range
$13.39
$24.29
Volume
431,593 shs
Average Volume
1.33 million shs
Market Capitalization
$2.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.40

Covetrus MarketRank™ Forecast

Analyst Rating
Hold
1.83 Rating Score
Upside/​Downside
2.8% Upside
$21.40 Price Target
Short Interest
Healthy
4.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of Covetrus in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.04 M Sold Last Quarter
Proj. Earnings Growth
21.95%
From $0.82 to $1.00 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Computer And Technology Sector

384th out of 666 stocks

Drug Stores & Proprietary Stores Industry

3rd out of 6 stocks

CVET stock logo

About Covetrus (NASDAQ:CVET) Stock

Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.

Covetrus Stock Up 0.1 %

NASDAQ:CVET traded up $0.02 on Friday, hitting $20.81. 1,254,940 shares of the company were exchanged, compared to its average volume of 930,528. The company has a market cap of $2.91 billion, a PE ratio of -208.10 and a beta of 1.67. Covetrus has a 12 month low of $13.39 and a 12 month high of $24.49. The stock has a fifty day moving average of $20.74 and a 200-day moving average of $18.35. The company has a current ratio of 1.88, a quick ratio of 1.08 and a debt-to-equity ratio of 0.65.

Wall Street Analysts Forecast Growth

CVET has been the subject of several research analyst reports. William Blair downgraded shares of Covetrus from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 25th. The Goldman Sachs Group dropped their price objective on shares of Covetrus from $18.00 to $16.00 and set a "sell" rating for the company in a research note on Thursday, May 19th. Barclays cut shares of Covetrus from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $26.00 to $21.00 in a research report on Thursday, May 26th. Raymond James cut shares of Covetrus from an "outperform" rating to a "market perform" rating in a research report on Monday, May 23rd. Finally, Stifel Nicolaus cut shares of Covetrus from a "buy" rating to a "hold" rating and set a $22.00 target price for the company. in a research report on Monday, June 13th. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. Based on data from MarketBeat, Covetrus presently has a consensus rating of "Hold" and an average price target of $21.40.

Insiders Place Their Bets

In other Covetrus news, Director Edward Mcnamara sold 34,525 shares of the company's stock in a transaction on Thursday, June 16th. The shares were sold at an average price of $20.52, for a total transaction of $708,453.00. Following the transaction, the director now owns 31,807 shares in the company, valued at $652,679.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Edward Mcnamara sold 34,525 shares of the stock in a transaction dated Thursday, June 16th. The shares were sold at an average price of $20.52, for a total value of $708,453.00. Following the completion of the sale, the director now owns 31,807 shares in the company, valued at $652,679.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Benjamin Wolin sold 5,293 shares of the stock in a transaction dated Tuesday, July 12th. The shares were sold at an average price of $20.75, for a total transaction of $109,829.75. Following the completion of the sale, the chief executive officer now owns 198,238 shares of the company's stock, valued at approximately $4,113,438.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,403 shares of company stock worth $1,037,392. Insiders own 0.40% of the company's stock.

Receive CVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

CVET Stock News Headlines

Covetrus Announces Retirement of Matthew Foulston
Form PRER14A COVETRUS, INC. - StreetInsider.com
Covetrus (CVET) Q2 Earnings Match Estimates
See More Headlines
Receive CVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

CVET Company Calendar

Last Earnings
2/28/2021
Today
8/15/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Drug stores & proprietary stores
Sub-Industry
N/A
Current Symbol
NASDAQ:CVET
Fax
N/A
Employees
5,710
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.40
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+2.7%
Consensus Rating
Hold
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$-54,000,000.00
Pretax Margin
-0.56%

Debt

Sales & Book Value

Annual Sales
$4.58 billion
Cash Flow
$2.19 per share
Book Value
$10.97 per share

Miscellaneous

Free Float
139,131,000
Market Cap
$2.92 billion
Optionable
Not Optionable
Beta
1.68

Key Executives

  • Mr. Benjamin Wolin (Age 46)
    Pres, CEO & Director
    Comp: $1.02M
  • Mr. Matthew J. Foulston (Age 57)
    Exec. VP & Global CFO
    Comp: $624.66k
  • Ms. Georgina Wraight (Age 47)
    Exec. VP & Pres of Global Technology Solutions
    Comp: $563.4k
  • Mr. Dustin k. Finer (Age 52)
    Chief Admin. Officer
    Comp: $552.67k
  • Mr. Matthew Malenfant (Age 60)
    Chief Commercial Officer
    Comp: $533.62k
  • Ms. Rebecca Kidd (Age 53)
    Head of Operations & Operational Excellence
  • Mr. Andrew B. Coxhead (Age 53)
    VP, Corp. Controller & Chief Accounting Officer
  • Mr. Nicholas Michael Jansen
    VP of Investor Relations
  • Ms. Ditte Marstrand Wulf (Age 51)
    Global Chief HR Officer
  • Mr. Russell Cooke (Age 56)
    Sr. VP & Operational CFO













CVET Stock - Frequently Asked Questions

Should I buy or sell Covetrus stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last twelve months. There are currently 1 sell rating and 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CVET shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVET, but not buy additional shares or sell existing shares.
View CVET analyst ratings
or view top-rated stocks.

What is Covetrus' stock price forecast for 2022?

6 equities research analysts have issued 12-month target prices for Covetrus' shares. Their CVET share price forecasts range from $16.00 to $27.00. On average, they expect the company's share price to reach $21.40 in the next twelve months. This suggests a possible upside of 2.8% from the stock's current price.
View analysts price targets for CVET
or view top-rated stocks among Wall Street analysts.

How have CVET shares performed in 2022?

Covetrus' stock was trading at $19.97 at the beginning of 2022. Since then, CVET stock has increased by 4.3% and is now trading at $20.82.
View the best growth stocks for 2022 here
.

When is Covetrus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CVET earnings forecast
.

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) announced its quarterly earnings results on Sunday, February, 28th. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.05. The firm earned $1.12 billion during the quarter, compared to the consensus estimate of $1.06 billion. Covetrus had a negative net margin of 0.28% and a positive trailing twelve-month return on equity of 6.83%. The firm's revenue for the quarter was up 11.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.18 EPS.

What is Benjamin Wolin's approval rating as Covetrus' CEO?

25 employees have rated Covetrus Chief Executive Officer Benjamin Wolin on Glassdoor.com. Benjamin Wolin has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (0.95%), Alpine Associates Management Inc. (0.90%), Frontier Capital Management Co. LLC (0.80%), Jennison Associates LLC (0.67%), Principal Financial Group Inc. (0.46%) and Candriam S.C.A. (0.45%). Insiders that own company stock include Anthony C Jr Providenti, Benjamin Shaw, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Erin Powers Brennan, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis and Timothy Ludlow.
View institutional ownership trends
.

How do I buy shares of Covetrus?

Shares of CVET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $20.82.

How much money does Covetrus make?

Covetrus (NASDAQ:CVET) has a market capitalization of $2.91 billion and generates $4.58 billion in revenue each year. The company earns $-54,000,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Covetrus have?

The company employs 5,710 workers across the globe.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The official website for the company is www.henryscheinvet.com. The company can be reached via phone at (888) 280-2221 or via email at nicholas.jansen@covetrus.com.

This page (NASDAQ:CVET) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.